<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02253771</url>
  </required_header>
  <id_info>
    <org_study_id>Orth-001</org_study_id>
    <nct_id>NCT02253771</nct_id>
  </id_info>
  <brief_title>Shockwave Therapy for Acute Low Back Pain</brief_title>
  <official_title>Shockwave Therapy for Acute Low Back Pain: a Randomized Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether shockwave therapy is more effective in the&#xD;
      treatment of unspecific acute low back pain than sham therapy.&#xD;
&#xD;
      60 patients with acute low back pain will be recruited to a single-blinded, randomized,&#xD;
      placebo-controlled trial. They are randomized to receive either shockwave therapy or sham&#xD;
      treatment by a identically looking device for 4 weeks, twice a week. Additionally patients&#xD;
      receive physiotherapy twice a week and are allowed to take an anti-inflammatory drug, if&#xD;
      necessary for even 4 weeks. The primary outcome variable will be measured at day 0, every&#xD;
      week during treatment (day 7; 14; 21 and 28) and up to 4 weeks after the last treatment. The&#xD;
      clinical outcome will be primarily measured by pain intensity using a visual analogue scale.&#xD;
      Secondary outcome measures are Oswestry Disability Index, Beck's Pain Depression Scale,&#xD;
      Roland Morris Disability Questionnaire and the EQ-5D. Data will be analysed for the&#xD;
      difference in change of scores between groups using one-way t-test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Actual">January 15, 2019</completion_date>
  <primary_completion_date type="Actual">September 13, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain, using visual analogue scale (VAS)</measure>
    <time_frame>Day 0; 7; 14; 21; 28, after 6 and 8 weeks.</time_frame>
    <description>Change in pain, using visual analogue scale (VAS 1-10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in other clinical questionnaires (Oswestry disability Index)</measure>
    <time_frame>day 0; 7; 14; 21, after 6 and 8 weeks.</time_frame>
    <description>Oswestry disability Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in other clinical questionnaires (Beck's depression scale)</measure>
    <time_frame>day 0; 7; 14; 21, after 6 and 8 weeks.</time_frame>
    <description>Beck's depression scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in other clinical questionnaires (EQ-5D)</measure>
    <time_frame>day 0; 7; 14; 21, after 6 and 8 weeks.</time_frame>
    <description>EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in other clinical questionnaires (Roland-Morris-Score)</measure>
    <time_frame>day 0; 7; 14; 21, after 6 and 8 weeks.</time_frame>
    <description>Roland-Morris-Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Acute Low Back Pain (Low Back Pain for Less Than 3 Months)</condition>
  <arm_group>
    <arm_group_label>shockwave therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>shockwave therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sham shockwave therapy by an identically looking device without any function</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>shockwave therapy</intervention_name>
    <description>Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week</description>
    <arm_group_label>shockwave therapy</arm_group_label>
    <other_name>EMS Swiss Dolorclast® Classic (EMS Electro Medical Systems S.a.)</other_name>
    <other_name>CE Certificate: 0124</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo shockwave therapy</intervention_name>
    <description>sham shockwave therapy by an identically looking device without any function</description>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        low back pain for less than 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with relevant leg pain&#xD;
&#xD;
          -  Patients with spine operations in the past&#xD;
&#xD;
          -  neurologic symptoms&#xD;
&#xD;
          -  scoliosis with Cobb angle &gt; 10°&#xD;
&#xD;
          -  Patients experienced in shock wave therapy&#xD;
&#xD;
          -  Patientes with ongoing therapy with blood diluting drugs such as phenprocumon&#xD;
&#xD;
          -  Patients with osteoporosis&#xD;
&#xD;
          -  Patients with back pain after trauma&#xD;
&#xD;
          -  Patients with infective diseases or tumor diseases&#xD;
&#xD;
          -  Patients with relevant psychological diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niklas Deventer, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Münster, Klinik für Allgemeine Orthopädie und Tumororthopädie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Schulte, Prof. Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Orthopaedics and Trauma Surgery, University Hospital, Ruhr University Bochum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Lange, Dr. med., MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Orthopaedics and Trauma Surgery, University Hospital, Ruhr University Bochum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Allgemeine Orthopädie und Tumororthopädie</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Barker KL, Elliott CJ, Sackley CM, Fairbank JC. Treatment of chronic back pain by sensory discrimination training. A Phase I RCT of a novel device (FairMed) vs. TENS. BMC Musculoskelet Disord. 2008 Jun 28;9:97. doi: 10.1186/1471-2474-9-97.</citation>
    <PMID>18588702</PMID>
  </reference>
  <reference>
    <citation>Seco J, Kovacs FM, Urrutia G. The efficacy, safety, effectiveness, and cost-effectiveness of ultrasound and shock wave therapies for low back pain: a systematic review. Spine J. 2011 Oct;11(10):966-77. doi: 10.1016/j.spinee.2011.02.002. Epub 2011 Apr 9. Review.</citation>
    <PMID>21482199</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 31, 2014</study_first_submitted>
  <study_first_submitted_qc>September 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Muenster</investigator_affiliation>
    <investigator_full_name>Niklas Deventer</investigator_full_name>
    <investigator_title>Dr. med. Niklas Deventer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

